Exelixis Initiating Phase 3 Pivotal Trial (COSMIC-313) of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinom
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| Exelixis, Inc. (NASDAQ: EXEL) | Delayed: 64.92 -0.39 (0.6%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $65.31 | 52 Week High | $17.00 | |||
| Open | $65.15 | 52 Week Low | $3.55 | |||
| Day High | $65.20 | P/E | N/A | |||
| Day Low | $63.91 | EPS | $-1.33 | |||
| Volume | 531,641 | |||||
